http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0939621-A4

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bf7cf645ac88c195eeeb2e0f3a2ff553
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-322
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-312
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1135
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
filingDate 1997-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22293a93185731f3fe282e794786b47e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33c91292aa5a83b8389a8c30eda620fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_839ff2ef4c4e9a5cf15da914864cb89a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b67c2e449540fad414b7677f5ef78cb0
publicationDate 2005-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-0939621-A4
titleOfInvention INHIBITION OF BCL-2 PROTEIN EXPRESSION BY LIPOSOMAL ANTISENSE OLIGODE OXYNUCLEOTIDE
abstract The present invention provides novel compositions and methods for use in the treatment of Bcl-2-associated diseases like cancer, specifically, in the treatment of follicular lymphoma (FL). The compositions contain antisense oligonucleotides that hybridize to Bcl-2 nucleic acids, the gene products of which are known to interact with the tumorigenic protein Bcl-2. Used alone, or in conjunction with other antisense oligonucleotides, these compositions inhibit the proliferation of FL cancer cells.
priorityDate 1996-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9503788-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9508350-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15764346
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87059597
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID425562
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6029
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21292785
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226425662
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID45051774
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87058072
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226402925
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6251
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID67955
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226405867
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24749
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID517204
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226405868
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226417419
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226411093
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226413457
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226417420
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226446069
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406087
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226398597
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11177
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393829
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394438
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226420348
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393819
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226405512
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226398598
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393830
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21226081
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399539
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID75143
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394880
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398641
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6175
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226410101
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409987
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226411934
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID104981
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3423265
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6235
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393946
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5819
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406714
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID12310447
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID449005
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21872864
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226446067
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21910379
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15793
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23830
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14710
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226411210
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406715

Total number of triples: 86.